Covid-19 Antibody

Pic:getty/dzmitrydzemidovich

Long-COVID personalized medicine enters Phase 2 trial

By Rachel Arthur

GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All